sNDA for Gedatolisib Submitted to FDA in PIK3CA-Mutant Breast Cancer

A supplemental New Drug Application (sNDA) for the drug Gedatolisib has been submitted to the U.S. FDA for treating PIK3CA-mutant breast cancer, signaling a regulatory step towards potential approval.

This Wire brief sits within Fusion42's coverage of Biotech.